Jakobi Annika, Lühr Armin, Stützer Kristin, Bandurska-Luque Anna, Löck Steffen, Krause Mechthild, Baumann Michael, Perrin Rosalind, Richter Christian
OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf , Dresden , Germany.
OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf , Dresden , Germany ; German Cancer Consortium (DKTK), Partner Site Dresden , Dresden , Germany ; German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Front Oncol. 2015 Nov 20;5:256. doi: 10.3389/fonc.2015.00256. eCollection 2015.
Presently used radiochemotherapy regimens result in moderate local control rates for patients with advanced head-and-neck squamous cell carcinoma (HNSCC). Dose escalation (DE) may be an option to improve patient outcome, but may also increase the risk of toxicities in healthy tissue. The presented treatment planning study evaluated the feasibility of two DE levels for advanced HNSCC patients, planned with either intensity-modulated photon therapy (IMXT) or proton therapy (IMPT).
For 45 HNSCC patients, IMXT and IMPT treatment plans were created including DE via a simultaneous integrated boost (SIB) in the high-risk volume, while maintaining standard fractionation with 2 Gy per fraction in the remaining target volume. Two DE levels for the SIB were compared: 2.3 and 2.6 Gy. Treatment plan evaluation included assessment of tumor control probabilities (TCP) and normal tissue complication probabilities (NTCP).
An increase of approximately 10% in TCP was estimated between the DE levels. A pronounced high-dose rim surrounding the SIB volume was identified in IMXT treatment. Compared to IMPT, this extra dose slightly increased the TCP values and to a larger extent the NTCP values. For both modalities, the higher DE level led only to a small increase in NTCP values (mean differences <2%) in all models, except for the risk of aspiration, which increased on average by 8 and 6% with IMXT and IMPT, respectively, but showed a considerable patient dependence.
Both DE levels appear applicable to patients with IMXT and IMPT since all calculated NTCP values, except for one, increased only little for the higher DE level. The estimated TCP increase is of relevant magnitude. The higher DE schedule needs to be investigated carefully in the setting of a prospective clinical trial, especially regarding toxicities caused by high local doses that lack a sound dose-response description, e.g., ulcers.
目前使用的放化疗方案对晚期头颈部鳞状细胞癌(HNSCC)患者的局部控制率中等。剂量递增(DE)可能是改善患者预后的一种选择,但也可能增加健康组织中毒性的风险。本治疗计划研究评估了两种DE水平对晚期HNSCC患者的可行性,分别采用调强光子治疗(IMXT)或质子治疗(IMPT)进行计划。
为45例HNSCC患者创建了IMXT和IMPT治疗计划,包括通过在高危体积内进行同步整合加量(SIB)来实现DE,同时在其余靶体积中保持每分次2 Gy的标准分割。比较了SIB的两种DE水平:2.3和2.6 Gy。治疗计划评估包括肿瘤控制概率(TCP)和正常组织并发症概率(NTCP)的评估。
估计DE水平之间TCP增加约10%。在IMXT治疗中,在SIB体积周围发现了明显的高剂量边缘。与IMPT相比,这一额外剂量略微增加了TCP值,并在更大程度上增加了NTCP值。对于这两种模式,除了误吸风险外,较高的DE水平在所有模型中仅导致NTCP值略有增加(平均差异<2%),IMXT和IMPT的误吸风险分别平均增加8%和6%,但显示出相当大的患者个体差异。
两种DE水平似乎都适用于接受IMXT和IMPT治疗的患者,因为除了一项之外,所有计算出的NTCP值在较高DE水平下仅略有增加。估计的TCP增加幅度具有相关性。需要在前瞻性临床试验中仔细研究较高的DE方案,特别是关于缺乏可靠剂量反应描述的高局部剂量引起的毒性,例如溃疡。